Recon: Novo Nordisk asks FDA to block semaglutide compounding; Roche inks potential $1B gene therapy deal with Dyno
ReconJason Scott
CompoundingEuropeGlobalNorth AmericaRegulatory Intelligence/PolicySubmission and registrationUnited StatesUS Food and Drug Administration (FDA)